SCHEMBL6330783

SCHEMBL6330783

CC/C(Nc1ccc(CC(N)=O)cc1)=C1/C(=O)Nc2cc(OC)c(OC)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 4/20 0.44
KDM1A O60341 1/20 0.42
EPHX2 P34913 1/20 0.42
PDPK1 O15530 1/20 0.39
CHEK1 O14757 3/20 0.38
EGFR P00533 1/20 0.37
FLT4 P35916 1/20 0.37
KDR P35968 1/20 0.37
FLT3 P36888 1/20 0.37
THRB P10828 1/20 0.37
BCHE P06276 1/20 0.37
ACHE P22303 1/20 0.37
AKT2 P31751 1/20 0.37
BRD4 O60885 1/20 0.37
CHEK2 O96017 1/20 0.36
KIT P10721 1/20 0.36
MARK3 P27448 1/20 0.36
MAPK1 P28482 1/20 0.36
AKT1 P31749 1/20 0.36
MARK2 Q7KZI7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6330792 1.00 RET (0.44) RETKDM1AEPHX2PDPK1CHEK1
SCHEMBL7474775 0.91 RET (0.47) RETEPHX2EGFRFLT4KDR
SCHEMBL6329199 0.91 RET (0.47) RETEPHX2EGFRFLT4KDR
SCHEMBL6329207 0.91 RET (0.47) RETEPHX2EGFRFLT4KDR
SCHEMBL6336916 0.90 RET (0.43) RETEPHX2PDPK1CHEK1EGFR
SCHEMBL6336920 0.90 RET (0.43) RETEPHX2PDPK1CHEK1EGFR
SCHEMBL6329107 0.89 RET (0.44) RETEPHX2PDPK1CHEK1EGFR
SCHEMBL6329095 0.89 RET (0.44) RETEPHX2PDPK1CHEK1EGFR
SCHEMBL6337231 0.88 CHEK1 (0.45) RETEPHX2CHEK1EGFRBCHE
SCHEMBL6332672 0.88 RET (0.45) RETEPHX2CHEK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009898-A1 New substituted indolinones, their manufacture and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-01-13 US disclosed
US-6794395-B1 Substituted indolinones, their manufacture and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009898-A1 New substituted indolinones, their manufacture and their use as medicaments CCNE1, CDK1, CCNI RET 154/4885KDM1A 494/4885EPHX2 3324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.